Wave Life Sciences presents a rare split-signal setup. Short sellers are building positions hard. Options traders are piling into calls. Analysts keep Buy ratings but are slashing targets. All three moved sharply in the same week.
Short interest hit 10.7% of free float on May 18. That's up 26.7% in a single week and 32.9% over the past month. In absolute terms, roughly 17.9 million shares are now short.
Despite the rapid buildup, the borrow market is anything but strained. Availability sits at 1,642% — meaning for every share currently lent out, more than 16 additional shares remain available to borrow. That is an exceptionally loose lending pool. Short sellers face no friction building or maintaining positions here.
Cost to borrow rose 66% week-on-week. But in absolute terms it remains negligible at 0.50% annualised. The CTB spike reflects the surge in short demand, not a tightening supply picture.
The options signal cuts against the short sellers. WVE's put-call ratio collapsed to 0.16 on May 18 — down from a 20-day average of 0.64. That's 2.4 standard deviations below the mean, near the 52-week low of 0.05.
When the stock fell 5.5% on May 18, options traders responded by buying calls, not puts. The PCR had been running around 0.85 through late April. It dropped sharply after May 1 and plunged again yesterday. That is an aggressive shift in options positioning.
The ORTEX short score stands at 53.7, up from 48.9 two weeks ago — reflecting the recent increase in short pressure.
Five analysts lowered price targets between late March and early May — all while maintaining Buy or Overweight ratings. The cuts were steep. Truist Securities dropped its target from $50 to $15. Canaccord went from $52 to $43. Wells Fargo moved from $27 to $13.
The mean analyst target is now $22.56 against a closing price of $6.40. That implies roughly 252% upside to consensus — an extreme gap that reflects either deep conviction in the RNA platform or targets that haven't fully caught up with the stock's 60% YTD decline.
The bear case centres on disappointing Phase 1 trial data and a net deficit of $137.8 million. The bull case points to the PRISM platform, the INLIGHT trial results, and an Arrowhead Pharmaceuticals partnership.
The most concrete vote of confidence on record came from RA Capital Management, a 10% owner with a board seat. The firm bought roughly 8.8 million shares across three days in late March — spending approximately $55.5 million at prices between $6.06 and $6.50. The stock trades near those same levels today.
That purchase still sits underwater. It also represents a major holder doubling down near current prices.
What to watch: Whether the PCR collapse is a one-day call-buying spike or a sustained shift in options sentiment — and whether the short position keeps building into the August 3 earnings date.
See the live data behind this article on ORTEX.
Open WVE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
